Mauro Avanzi, MD, PhD, has been appointed chief medical officer of Shoreline Biosciences, a biopharmaceutical company focused on developing cellular immunotherapies based on induced pluripotent stem cells.
Dr. Avanzi most recently served as vice president of clinical development at Neogene Therapeutics, according to a Feb. 21 release announcing his appointment. While at Neogene, he oversaw clinical studies on TCR T cells targeting neoantigens.
Dr. Avanzi has also held a variety of positions at Kite Pharma, including medical director and senior medical director before serving as executive medical director from 2020 to 2021, according to LinkedIn.